Cory L. Painter

589 total citations
15 papers, 470 citations indexed

About

Cory L. Painter is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Cory L. Painter has authored 15 papers receiving a total of 470 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Cory L. Painter's work include Cancer Cells and Metastasis (5 papers), Advanced Breast Cancer Therapies (4 papers) and Cancer-related Molecular Pathways (4 papers). Cory L. Painter is often cited by papers focused on Cancer Cells and Metastasis (5 papers), Advanced Breast Cancer Therapies (4 papers) and Cancer-related Molecular Pathways (4 papers). Cory L. Painter collaborates with scholars based in United States and United Kingdom. Cory L. Painter's co-authors include Zhengming Yan, James G. Christensen, Cathy C. Zhang, Cathy Zhang, Maruja E. Lira, Qin Zhang, Anthony Wong, Maria E. Arango, Kenna Anderes and Enhong Chen and has published in prestigious journals such as PLoS ONE, Cancer Research and Clinical Cancer Research.

In The Last Decade

Cory L. Painter

15 papers receiving 465 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cory L. Painter United States 10 278 190 83 70 66 15 470
Jin‐Qiu Chen United States 10 313 1.1× 282 1.5× 40 0.5× 86 1.2× 33 0.5× 17 602
Christoph Rösli Switzerland 8 245 0.9× 137 0.7× 29 0.3× 78 1.1× 168 2.5× 10 487
Ingrid Babel Spain 8 301 1.1× 137 0.7× 40 0.5× 84 1.2× 135 2.0× 9 483
Mary Luz Uribe Spain 8 259 0.9× 153 0.8× 104 1.3× 81 1.2× 33 0.5× 14 513
Otto Kauko Finland 11 441 1.6× 134 0.7× 69 0.8× 78 1.1× 9 0.1× 18 556
Ziad J. Sahab United States 12 236 0.8× 109 0.6× 24 0.3× 57 0.8× 37 0.6× 15 407
Sherianne Ricks United States 7 266 1.0× 195 1.0× 52 0.6× 71 1.0× 20 0.3× 8 524
Indranil Basu United States 9 344 1.2× 158 0.8× 50 0.6× 33 0.5× 42 0.6× 17 543
Martin Udart Germany 10 248 0.9× 214 1.1× 36 0.4× 47 0.7× 45 0.7× 15 428
Caroline Coghlin United Kingdom 6 205 0.7× 185 1.0× 106 1.3× 134 1.9× 27 0.4× 10 447

Countries citing papers authored by Cory L. Painter

Since Specialization
Citations

This map shows the geographic impact of Cory L. Painter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cory L. Painter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cory L. Painter more than expected).

Fields of papers citing papers by Cory L. Painter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cory L. Painter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cory L. Painter. The network helps show where Cory L. Painter may publish in the future.

Co-authorship network of co-authors of Cory L. Painter

This figure shows the co-authorship network connecting the top 25 collaborators of Cory L. Painter. A scholar is included among the top collaborators of Cory L. Painter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cory L. Painter. Cory L. Painter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Whalen, Pamela, Amy Jackson-Fisher, Cory L. Painter, et al.. (2019). Abstract 4925: Development of a novel PTK7 immunohistochemistry (IHC) assay and analytical validation in epithelial malignancies of lung, breast and ovary. Cancer Research. 79(13_Supplement). 4925–4925. 1 indexed citations
2.
Pirie‐Shepherd, Steven, Cory L. Painter, Pamela Whalen, et al.. (2017). Detecting expression of 5T4 in CTCs and tumor samples from NSCLC patients. PLoS ONE. 12(7). e0179561–e0179561. 7 indexed citations
3.
Koehler, María, Todd VanArsdale, David J. Shields, et al.. (2014). Mechanism of Action for Combined CDK4/6 and Er Inhibition in ER Positive Breast Cancer. Annals of Oncology. 25. i21–i21. 5 indexed citations
4.
Lee, Nathan V., Jing Yuan, Joan Cao, et al.. (2014). Abstract LB-136: Mechanistic exploration of combined CDK4/6 and ER inhibition in ER-positive breast cancer. Cancer Research. 74(19_Supplement). LB–136. 3 indexed citations
5.
Zhang, Cathy C., Zhengming Yan, Anand Giddabasappa, et al.. (2014). Comparison of dynamic contrast‐enhanced MR, ultrasound and optical imaging modalities to evaluate the antiangiogenic effect of PF‐03084014 and sunitinib. Cancer Medicine. 3(3). 462–471. 17 indexed citations
6.
Zhang, Cathy C., Zhengming Yan, Douglas D. Fang, et al.. (2013). Synergistic Effect of the γ-Secretase Inhibitor PF-03084014 and Docetaxel in Breast Cancer Models. Stem Cells Translational Medicine. 2(3). 233–242. 78 indexed citations
7.
Zhang, Cathy C., Adam Pavlı́c̀ek, Qin Zhang, et al.. (2012). Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models. Clinical Cancer Research. 18(18). 5008–5019. 53 indexed citations
8.
Zhang, Cathy C., Zhengming Yan, Douglas D. Fang, et al.. (2012). Abstract 3492: γ-secretase inhibitor PF-03084014 diminishes the tumor-initiating cells and demonstrates synergy with docetaxel in breast cancer xenograft models. Cancer Research. 72(8_Supplement). 3492–3492. 1 indexed citations
9.
Zhang, Cathy C., Zhengming Yan, Wenlin Li, et al.. (2011). [18F]FLT–PET Imaging Does Not Always “Light Up” Proliferating Tumor Cells. Clinical Cancer Research. 18(5). 1303–1312. 62 indexed citations
10.
Zhang, Cathy C., Zhengming Yan, Qin Zhang, et al.. (2010). PF-03732010: A Fully Human Monoclonal Antibody against P-Cadherin with Antitumor and Antimetastatic Activity. Clinical Cancer Research. 16(21). 5177–5188. 58 indexed citations
11.
Nguyen, Leslie, Wei-Zhu Zhong, Cory L. Painter, et al.. (2010). Quantitative analysis of PD 0332991 in xenograft mouse tumor tissue by a 96-well supported liquid extraction format and liquid chromatography/mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 53(3). 228–234. 32 indexed citations
12.
Zhang, Cathy, Zhengming Yan, Cory L. Painter, et al.. (2009). PF-00477736 Mediates Checkpoint Kinase 1 Signaling Pathway and Potentiates Docetaxel-Induced Efficacy in Xenografts. Clinical Cancer Research. 15(14). 4630–4640. 45 indexed citations
13.
Bandow, Julia E., John D. Baker, Matthias Berth, et al.. (2008). Improved image analysis workflow for 2‐D gels enables large‐scale 2‐D gel‐based proteomics studies – COPD biomarker discovery study. PROTEOMICS. 8(15). 3030–3041. 65 indexed citations
14.
Zhang, Cathy, Zhengming Yan, Maria E. Arango, Cory L. Painter, & Kenna Anderes. (2008). Advancing Bioluminescence Imaging Technology for the Evaluation of Anticancer Agents in the MDA-MB-435-HAL-Luc Mammary Fat Pad and Subrenal Capsule Tumor Models. Clinical Cancer Research. 15(1). 238–246. 32 indexed citations
15.
Slemmon, J. Randall, et al.. (2006). Distribution of Aβ peptide in whole blood. Journal of Chromatography B. 846(1-2). 24–31. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026